Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma
Malignant tumours
doi 10.18027/2224-5057-2017-7-4-63-76
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Russian Society of Clinical Oncology